Loading...

Infant Bacterial Therapeutics

OM:IBT B
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IBT B
OM
SEK2B
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
IBT B Share Price and Events
7 Day Returns
6.9%
OM:IBT B
2.3%
SE Pharmaceuticals
0.8%
SE Market
1 Year Returns
1.9%
OM:IBT B
6.2%
SE Pharmaceuticals
-0.6%
SE Market
IBT B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Infant Bacterial Therapeutics (IBT B) 6.9% 4.8% 17.9% 1.9% 388.2% -
SE Pharmaceuticals 2.3% -2% 2% 6.2% 11.7% 7%
SE Market 0.8% -2.3% 2.4% -0.6% 14.3% 18.2%
1 Year Return vs Industry and Market
  • IBT B underperformed the Pharmaceuticals industry which returned 6.2% over the past year.
  • IBT B outperformed the Market in Sweden which returned -0.6% over the past year.
Price Volatility
IBT B
Industry
5yr Volatility vs Market

Value

 Is Infant Bacterial Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Infant Bacterial Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is SEK199.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Infant Bacterial Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Infant Bacterial Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:IBT B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK-2.86
OM:IBT B Share Price ** OM (2019-05-17) in SEK SEK199.2
Europe Pharmaceuticals Industry PE Ratio Median Figure of 43 Publicly-Listed Pharmaceuticals Companies 21.86x
Sweden Market PE Ratio Median Figure of 323 Publicly-Listed Companies 16.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Infant Bacterial Therapeutics.

OM:IBT B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:IBT B Share Price ÷ EPS (both in SEK)

= 199.2 ÷ -2.86

-69.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Infant Bacterial Therapeutics is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Infant Bacterial Therapeutics is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does Infant Bacterial Therapeutics's expected growth come at a high price?
Raw Data
OM:IBT B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -69.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-2.9%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.93x
Sweden Market PEG Ratio Median Figure of 235 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Infant Bacterial Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Infant Bacterial Therapeutics's assets?
Raw Data
OM:IBT B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK49.53
OM:IBT B Share Price * OM (2019-05-17) in SEK SEK199.2
Sweden Pharmaceuticals Industry PB Ratio Median Figure of 19 Publicly-Listed Pharmaceuticals Companies 4.02x
Sweden Market PB Ratio Median Figure of 567 Publicly-Listed Companies 2.46x
OM:IBT B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:IBT B Share Price ÷ Book Value per Share (both in SEK)

= 199.2 ÷ 49.53

4.02x

* Primary Listing of Infant Bacterial Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Infant Bacterial Therapeutics is good value based on assets compared to the SE Pharmaceuticals industry average.
X
Value checks
We assess Infant Bacterial Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Infant Bacterial Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Infant Bacterial Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-2.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Infant Bacterial Therapeutics expected to grow at an attractive rate?
  • Unable to compare Infant Bacterial Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Infant Bacterial Therapeutics's earnings growth to the Sweden market average as it is expected to be loss making during the next 1-3 years.
  • Infant Bacterial Therapeutics's revenue growth is expected to exceed the Sweden market average.
Annual Growth Rates Comparison
Raw Data
OM:IBT B Future Growth Rates Data Sources
Data Point Source Value (per year)
OM:IBT B Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -2.9%
OM:IBT B Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 72.4%
Sweden Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.5%
Sweden Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.6%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:IBT B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:IBT B Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 359 -32 1
2022-12-31 134 -139 1
2021-12-31 0 -191 1
2020-12-31 0 -151 1
2019-12-31 0 -106 1
OM:IBT B Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 -45 -32
2018-12-31 -47 -41
2018-09-30 0 -28 -26
2018-06-30 0 -28 -22
2018-03-31 0 -34 -37
2017-12-31 0 -35 -36
2017-09-30 0 -42 -41
2017-06-30 0 -41 -44
2017-03-31 0 -42 -42
2016-12-31 0 -40 -38
2016-09-30 0 -34 -19
2016-06-30 -33 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Infant Bacterial Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Infant Bacterial Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:IBT B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Infant Bacterial Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:IBT B Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.47 -2.47 -2.47 1.00
2022-12-31 -10.62 -10.62 -10.62 1.00
2021-12-31 -15.30 -15.30 -15.30 1.00
2020-12-31 -12.84 -12.84 -12.84 1.00
2019-12-31 -9.45 -9.45 -9.45 1.00
OM:IBT B Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 -2.86
2018-12-31 -3.76
2018-09-30 -2.78
2018-06-30 -2.76
2018-03-31 -5.58
2017-12-31 -6.46
2017-09-30 -6.60
2017-06-30 -7.37
2017-03-31 -7.63
2016-12-31 -8.42
2016-09-30 -6.10
2016-06-30 -3.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Infant Bacterial Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Infant Bacterial Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Infant Bacterial Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Infant Bacterial Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Infant Bacterial Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Infant Bacterial Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Infant Bacterial Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Infant Bacterial Therapeutics's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Infant Bacterial Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Infant Bacterial Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:IBT B Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -32.15 1.09 30.12
2018-12-31 -40.61 1.09 38.33
2018-09-30 0.00 -25.52 0.96 23.64
2018-06-30 0.00 -22.12 0.96 20.53
2018-03-31 0.12 -36.74 0.96 35.89
2017-12-31 0.24 -36.16 0.96 35.42
2017-09-30 0.35 -41.20 0.83 40.89
2017-06-30 0.40 -44.33 -1.71 46.81
2017-03-31 0.28 -41.50 -1.71 43.72
2016-12-31 0.16 -38.11 -1.71 40.14
2016-09-30 0.05 -19.17 -1.00 30.48
2016-06-30 -6.63 3.09 23.89
2016-03-31 -0.35 3.09 17.75
2015-12-31 -0.02 3.09 17.48
2014-12-31 -0.02 6.59
2013-12-31 0.00 0.23
2012-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Infant Bacterial Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Infant Bacterial Therapeutics has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Infant Bacterial Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Infant Bacterial Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Infant Bacterial Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Infant Bacterial Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Infant Bacterial Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Infant Bacterial Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Infant Bacterial Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Infant Bacterial Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Infant Bacterial Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Infant Bacterial Therapeutics Company Filings, last reported 1 month ago.

OM:IBT B Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 556.03 0.00 540.51
2018-12-31 556.72 0.00 542.17
2018-09-30 580.86 0.00 566.79
2018-06-30 589.82 0.00 576.80
2018-03-31 589.15 0.00 581.08
2017-12-31 168.37 0.00 158.27
2017-09-30 79.01 0.00 67.18
2017-06-30 83.60 0.00 76.32
2017-03-31 96.66 0.00 84.67
2016-12-31 105.23 0.00 93.79
2016-09-30
2016-06-30 127.05 0.00 116.38
2016-03-31 74.81 0.00 44.41
2015-12-31 74.81 0.00 44.41
2014-12-31 11.03 0.00 1.05
2013-12-31 1.05 0.00 0.90
2012-12-31 0.05 0.00 0.05
  • Infant Bacterial Therapeutics has no debt.
  • Infant Bacterial Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Infant Bacterial Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Infant Bacterial Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.9% each year.
X
Financial health checks
We assess Infant Bacterial Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Infant Bacterial Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Infant Bacterial Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Infant Bacterial Therapeutics dividends.
If you bought SEK2,000 of Infant Bacterial Therapeutics shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Infant Bacterial Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Infant Bacterial Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:IBT B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 32 Stocks 3.4%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 243 Stocks 3.2%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.1%
Sweden Bottom 25% Dividend Yield 25th Percentile 1.8%
Sweden Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OM:IBT B Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Infant Bacterial Therapeutics has not reported any payouts.
  • Unable to verify if Infant Bacterial Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Infant Bacterial Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Infant Bacterial Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Infant Bacterial Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Infant Bacterial Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Infant Bacterial Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Infant Bacterial Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Staffan Strömberg
COMPENSATION SEK3,081,000
AGE 51
TENURE AS CEO 6.3 years
CEO Bio

Mr. Staffan Strömberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Strömberg serves as Vice President of Development and Regulatory Affairs at BioGaia AB. He has been with BioGaia AB since 2012. He has over 18 years of experience in the pharmaceutical industry. He served as Head of Medical Devices at the Swedish Medical Products Agency and Vice President of Nicox France. Mr. Strömberg served as Vice President Technical Development & Operations at Nicox SA and served as its Vice President of Drug Development since June 2005. His last position was Director of Neuroscience Portfolio Optimization at AstraZeneca plc. He previously held other positions within AstraZeneca, including Project Manager for the CINOD class (COX-inhibiting nitric oxide-donating compounds), including its lead compound HCT 3012, which NicOx is developing for the symptoms of osteoarthritis and which was partnered with AstraZeneca from 1998 to 2003. He has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan. Mr. Stromberg has also been Head of Research and Development at Swedish Orphan AB, where he was a member of the management team and responsible for strategic portfolio management at all stages of development. He holds M.Sc. in chemical engineering and Ph.D. in organic chemistry from the Royal Institute of Technology in, Stockholm, Sweden.

CEO Compensation
  • Staffan's compensation has increased whilst company is loss making.
  • Staffan's remuneration is about average for companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the Infant Bacterial Therapeutics management team in years:

1.8
Average Tenure
51
Average Age
  • The average tenure for the Infant Bacterial Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Staffan Strömberg

TITLE
Chief Executive Officer
COMPENSATION
SEK3M
AGE
51
TENURE
6.3 yrs

Daniel Mackey

TITLE
Chief Financial Officer
COMPENSATION
SEK2M
AGE
44
TENURE
2.3 yrs

Eamonn Connolly

TITLE
Chief Scientific Officer
COMPENSATION
SEK2M
AGE
61
TENURE
1.8 yrs

Anders Kronström

TITLE
Chief Operating Officer
AGE
51
TENURE
1.3 yrs

Jonas Rastad

TITLE
Chief Medical Officer
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Infant Bacterial Therapeutics board of directors in years:

2
Average Tenure
57
Average Age
  • The average tenure for the Infant Bacterial Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Peter Rothschild

TITLE
Chairman
COMPENSATION
SEK600K
AGE
68
TENURE
8.3 yrs

Anders Ekblom

TITLE
Director
COMPENSATION
SEK100K
AGE
64
TENURE
5.3 yrs

Margareta Hagman

TITLE
Director
COMPENSATION
SEK100K
AGE
52
TENURE
3.7 yrs

Anthon Jahreskog

TITLE
Director
COMPENSATION
SEK50K
AGE
38
TENURE
2 yrs

Eva Idén

TITLE
Director
COMPENSATION
SEK50K
AGE
52
TENURE
2 yrs

Lilian Wikström

TITLE
Director
AGE
57
TENURE
1 yrs

Kristina Nygren

TITLE
Director
AGE
57
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
21. Nov 18 Buy Daniel Mackey Individual 21. Nov 18 21. Nov 18 340 SEK120.50 SEK40,970
X
Management checks
We assess Infant Bacterial Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Infant Bacterial Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Salary Compare Well With Others?

Staffan Strömberg has been the CEO of Infant Bacterial Therapeutics AB (publ) (STO:IBT B) since 2013. … See our latest analysis for Infant Bacterial Therapeutics How Does Staffan Strömberg's Compensation Compare With Similar Sized Companies? … Our data indicates that Infant Bacterial Therapeutics AB (publ) is worth kr2.1b, and total annual CEO compensation is kr3.1m.

Simply Wall St -

Infant Bacterial Therapeutics (STO:IBT B) Shares Have Generated A Total Return Of 283% In The Last Three Years

For example, the Infant Bacterial Therapeutics AB (publ) (STO:IBT B) share price has soared 110% in the last three years. … With zero revenue generated over twelve months, we don't think that Infant Bacterial Therapeutics has proved its business plan yet. … Investors will be hoping that Infant Bacterial Therapeutics can make progress and gain better traction for the business, before it runs low on cash.

Simply Wall St -

Company Info

Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Details
Name: Infant Bacterial Therapeutics AB (publ)
IBT B
Exchange: OM
Founded: 2013
SEK2,236,255,852
11,226,184
Website: http://www.ibtherapeutics.com
Address: Infant Bacterial Therapeutics AB (publ)
Bryggargatan 10,
Stockholm,
Stockholm County, 111 21,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM IBT B Class B Shares OMX Nordic Exchange Stockholm SE SEK 29. Mar 2016
BST 9IB Class B Shares Boerse-Stuttgart DE EUR 29. Mar 2016
Number of employees
Current staff
Staff numbers
8
Infant Bacterial Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 22:52
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/06
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.